Last reviewed · How we verify
Anlotinib and 14C-labeled Anlotinib
Anlotinib and 14C-labeled Anlotinib is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Anlotinib and 14C-labeled Anlotinib |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anlotinib and 14C-labeled Anlotinib CI brief — competitive landscape report
- Anlotinib and 14C-labeled Anlotinib updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about Anlotinib and 14C-labeled Anlotinib
What is Anlotinib and 14C-labeled Anlotinib?
Anlotinib and 14C-labeled Anlotinib is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Who makes Anlotinib and 14C-labeled Anlotinib?
Anlotinib and 14C-labeled Anlotinib is developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (see full Chia Tai Tianqing Pharmaceutical Group Co., Ltd. pipeline at /company/chia-tai-tianqing-pharmaceutical-group-co-ltd).
What development phase is Anlotinib and 14C-labeled Anlotinib in?
Anlotinib and 14C-labeled Anlotinib is in Phase 1.